SIGA Technologies Inc

NASDAQ:SIGA

Earnings Call Analysis

SIGA Technologies Reports Strong Product Sales and Future Growth Potential

In the third quarter of 2024, SIGA Technologies achieved product revenues of $9 million, contributing to $53 million year-to-date, driven by diverse sales of TPOXX to the U.S. government and international markets, including a first sale to Africa. They hold $146 million in outstanding orders, positioning them for significant revenue in late 2024 and 2025. With a solid balance sheet featuring $99 million in cash, SIGA plans to pursue new contracts for TPOXX, targeting robust public health preparedness. Their recent licensing of monoclonal antibodies enhances growth avenues, underscoring a commitment to address serious health needs.

Strong Demand and Revenue Growth

SIGA Technologies continues to show resilience and solid performance, with total product revenue reaching $53 million for the nine months ending September 30, 2024, representing an increase compared to the previous year. The majority of revenue comes from TPOXX, including $23 million from oral formulations and $17 million from intravenous (IV) formulations sold to the U.S. government. Additionally, the third quarter alone accounted for $9 million in revenue, including the first significant delivery of oral TPOXX, valued at $8 million, to the U.S. Strategic National Stockpile (SNS) under a recent contract.

Healthy Order Pipeline

As of the end of Q3 2024, SIGA boasts outstanding procurement orders totaling $146 million, highlighting a strong demand for TPOXX. This includes a key $112.5 million order in July that has started to be fulfilled, with ongoing shipments slated to continue into 2025. This robust order backlogs bodes well for expected revenues in the remainder of this year and into next.

Financial Strength and Shareholder Returns

SIGA's financial health is evident with a cash balance of $99 million and no debt as of September 30, 2024. The company has also demonstrated commitment to returning value to shareholders, illustrated by a substantial $43 million cash dividend distributed in April 2024, amounting to $0.60 per share. The improvement in profitability is marked by net income of $1 million for Q3 and a total of $13 million year-to-date, a significant turnaround from the losses recorded in the previous year.

Future Growth and Expansion Initiatives

SIGA is actively pursuing strategies to enhance its product offerings and market position. A notable development is the exclusive licensing of a portfolio of preclinical monoclonal antibodies from Vanderbilt University, aimed at treating orthopoxviruses like smallpox and mpox. This initiative could attract further collaborations with government partners and new growth opportunities. The company’s proactive engagement in international markets is also notable, as seen in its recent entry into Africa with its first oral TPOXX sale to Morocco's Ministry of Health.

Guidance for 2024 and Beyond

Overall, SIGA anticipates a strong revenue outlook for 2024, underpinned by robust demand and strategic order fulfillment. Management expects to continue securing contracts that enhance TPOXX availability in the SNS and promote public health preparedness. Looking ahead, there are plans for a new SNS contract targeted for 2025, likely extending over a five to ten-year period, with the previous contract valued at $546 million. This, combined with existing and new product trajectories, positions SIGA favorably for sustainable growth.

Addressing Investor Concerns

In light of recent media reports concerning mpox patients possibly developing resistance to TPOXX, SIGA has provided reassurance. Management indicated that resistance remains low—at less than 1%—and primarily occurs in specific populations such as immunocompromised patients. Importantly, SIGA has not observed resistance in smallpox treatments, which is less likely given the nature of DNA viruses compared to more mutable RNA viruses like COVID-19. The overall safety and efficacy of TPOXX continue to be supported by extensive clinical data.

Earnings Call Transcript 2024-Q3

[Operator]

Good afternoon, ladies and gentlemen, and welcome to the SIGA Technologies Third Quarter 2024 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.

I would now like to turn the conference over to Diem Nguyen, Chief Executive Officer. Please go ahead.

[Diem Nguyen, executive]

Good afternoon, everyone, and thank you for joining today's call and the review of our business results for the third quarter of 2024. I am joined by Dan Luckshire, our Chief Financial Officer, and we appreciate this opportunity to provide an update on our company. After the update, we'll be happy to answer your questions.

I'm pleased to share that with $122 million of procurement orders secured in the third quarter, SIGA continues to sustain its strong business momentum. These new orders position us well to extend our strong year-to-date revenue performance, which is outpacing revenues in the comparable period last year.

Additionally, I would like to note that our product sales so far this year include a diverse mix of revenue sources, led by oral and IV TPOXX deliveries to the U.S. Strategic National Stockpile. Internationally, year-to-date sales include deliveries to new customers, one of which represents our first sales of oral TPOXX in Africa in response to a request from the Ministry of Health in Morocco.

At the end of the third quarter, outstanding procurement orders were $146 million. This significant balance of outstanding orders positions us to recognize substantial revenues in the fourth quarter of 2024 and into 2025, demonstrating the continued strong demand for TPOXX.

Please note that this outstanding order balance includes most of the $112.5 million order from the U.S. government under the 19C contract announced in July, which we began shipping towards the end of September and continued into October.

We believe year-to-date sales as well as the outstanding orders built over the past several months underscore our company's financial strength and resilience. Our focus continues to be on SIGA's long-term performance as we have multiple strategic opportunities to drive and expand our revenue base and earnings over time.

Looking forward, we believe securing a new contract for the continuing supply of TPOXX to the Strategic National Stockpile, or SNS, represents a significant opportunity to enhance our company's momentum and long-term earnings potential as well as do our part to advance our nation's public health preparedness. We believe our ongoing productive conversations with a wide range of government officials positions us well as we prepare for the Administration of Strategic Preparedness and Response, known as ASPR, to take the first step in the process, which we expect to result in a new contract for TPOXX.

As a reminder, ASPR is within the U.S. Department of Human Services, or HHS, and houses the Center for the Biomedical Advanced Research and Development Authority, or BARDA, and the SNS. We believe our dedicated team is well prepared to support this crucial public health initiative.

And based on these conversations, we are confident in the U.S. government's enduring commitment to maintaining robust public health preparedness and the supply of antiviral therapies to treat smallpox. Importantly, at SIGA, we believe that the effective pandemic preparedness requires both vaccines and antivirals as neither alone can fully address the complexity of an outbreak.

While vaccines play an important role preventing disease and building immunity, they may not be immediately available or effective for everyone. Antivirals, meanwhile, offer a critical line of defense by treating infections in real time and reducing the severity and spread of illness. Together, these tools provide a comprehensive approach to managing a pandemic, ensuring both preventive measures and timely treatments are available.

We anticipate working towards a new comprehensive long-term agreement spanning 5 to 10 years. As a frame of reference, our last contract executed in 2018 was valued at $546 million. Given the many changes anticipated to take place over the coming weeks in the federal government, the exact timing of the necessary steps remain to be determined.

Please keep in mind that health security is a bipartisan issue, with strong alignment across both parties and transcends elections and political considerations. This has been reinforced by our experience with administrations from both parties. In fact, our last 2 contracts were awarded under different administrations, specifically President Obama and President Trump.

In summary, we're targeting the issuance of a new SNS contract in 2025, which we expect would include initial order under such contract. Such a contract would further our shared goal of protecting public health through continued partnership with the U.S. government.

Shifting gears, I'm pleased to share that we've recently announced an exclusive license to the portfolio of our preclinical fully human monoclonal antibodies from the Vanderbilt University that have the potential to treat a broad range of orthopoxviruses, including smallpox and mpox.

This portfolio of monoclonals expands our pipeline, complements our TPOXX franchise and offers the potential for development of additional therapies in this space. Further, it opens the door to new long-term growth opportunities in collaboration with government partners to offset development investments.

The U.S. Department of Defense is currently funding the development of these monoclonals through Phase I via a third-party contract manufacturing organization with proven expertise in biologics development and manufacturing. Assuming the data are positive on these future studies, we plan to explore collaborations with government stakeholders and, with their input, pursue the development of these monoclonals to meet the needs of patients and public health.

Our efforts will strive to develop this portfolio over the next several years efficiently without requiring significant use of the company's cash resources to progress. The license marks an important step forward in our strategy to leverage our existing capabilities to create new opportunities for growth over the long term.

Regarding the TPOXX post-exposure prophylaxis program for smallpox, or PEP, we continue to collaborate with the CDC in consultation with the FDA to complete the analysis of samples collected to support the study's immunogenicity objective. The CDC recently began gearing up to perform the reanalysis and is targeted to complete its work in the first half of 2025. As such, we are planning for an FDA submission of the PEP indication in the third quarter of 2025.

As we announced on August 15, the National Institute of Allergy and Infectious Diseases, or NIAID, shared top line results from a preliminary analysis from the PALM 007 trial. While the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days for mpox patients in the Democratic Republic of Congo, who were treated with tecovirimat versus placebo, the results for this trial was not surprising due to the humanitarian considerations of the study design.

Nonetheless, we are encouraged by the data showing tecovirimat's potential benefit in 2 important patient groups: first, those patients treated early; and second, those with severe disease. We believe additional trials are warranted to explore the potential benefits of TPOXX as an mpox treatment in these and possibly other patient populations.

Several additional mpox studies are currently being conducted by trial sponsors around the world and are expected to help inform a deeper understanding of the potential of tecovirimat to benefit mpox patients. Four trials are currently enrolling patients, including STOMP, UNITY, Platinum-Canada and EPOXI.

The largest of these is STOMP, sponsored by NIAID and is enrolling patients primarily in the U.S. and South America. It's progressing well with about 670 patients enrolled as of the first week of October, up from 515 reported on our last call.

I would highlight that TPOXX has demonstrated a strong safety profile and is well tolerated by patients. This is supported by preclinical safety and toxicology studies in numerous animal models, including mpox-infected nonhuman primates, Phase III clinical data with healthy volunteers and clinical observations in disease patients.

Additionally, more than 2,000 mpox patients have participated in clinical trials to assess the efficacy of TPOXX for mpox treatment and more than 8,000 patients have been administered TPOXX for compassionate use as the preferred antiviral to treat mpox disease. Furthermore, TPOXX has demonstrated effectiveness as an antiviral and PEP treatment for survival and reduction of body lesions and viral load in nonhuman primates infected with lethal amounts of mpox virus.

Additionally, TPOXX has been shown to improve survival or reduced lesions in nonhuman primates infected with smallpox. Based on the totality of the scientific evidence, we believe this diverse and expansive collection of data sources highlights why TPOXX has received regulatory approval for smallpox in the U.S. and Canada and regulatory approval in the EU and the U.K. for a broad orthopox label, including smallpox and mpox.

In Japan, we are actively engaged in discussions with our partner Japan Biotechno Pharma and regulators regarding the pending new drug application for TPOXX to treat smallpox, mpox, cowpox and complications due to the vaccinia virus. Based on the standard review time line, we expect a final regulatory decision by early next year.

In summary, this is an exciting and dynamic time for SIGA. We are strong, resilient and profitable. Our strategy and prudent capital management is delivering solid results and we believe make us well positioned for the future.

Additionally, our TPOXX franchise meets a critical need for smallpox preparedness and our team has the expertise to drive long-term results, which we believe will produce sustainable growth and shareholder value over time.

With that, I'll turn it over to Dan to review the financial results in more detail.

[Daniel Luckshire, executive]

Thanks, Sam. As noted earlier in the call, SIGA's product sales for the 9 months ended September 30, 2024, continue to outpace product sales for the comparable period in 2023. Product revenue for the 9 months ended September 30, 2024, was $53 million. Of this amount, $9 million is related to the third quarter.

In the third quarter, there is an $8 million oral TPOXX delivery to the U.S. Strategic National Stockpile, or SNS, and $1 million of international sales. The $8 million oral TPOXX delivery represents the first delivery to the SNS in connection with the $112.5 million order under the 19C contract, which was announced in July. The international sales amount includes the first sale to Africa.

With respect to product revenues for the 9 months ended September 30, 2024, the $53 million amount comes from a diverse mix, including $23 million of oral TPOXX sales and $17 million of IV TPOXX sales to the U.S. government under the 19C contract, $12 million of international oral TPOXX sales to 12 countries and $1 million of oral TPOXX sales to the U.S. Department of Defense.

In addition to product-related revenues, the company also has had research and development revenue. For the 3 and 9 months ended September 30, 2024, research and development revenues were $1 million and $4 million, respectively.

Pretax operating income, which excludes interest income and taxes, was $0.5 million for the 3 months ended September 30, 2024. For the 9 months ended September 30, pretax operating income was $13 million. In comparison, there is a pretax operating loss for the 3 and 9 months ended September 30, 2023, of $1 million and $8 million, respectively.

Net income for the 3 months ended September 30, 2024, was $1 million. For the 9 months ended September 30, net income was $13 million. In turn, fully diluted income per share for the 3 months ended September 30, 2024, was $0.02. And for the 9 months ended September 30, fully diluted income per share was $0.19.

At September 30, 2024, the company continued to maintain a strong balance sheet, with a cash balance of $99 million and no debt. I would like to note that the company has maintained a strong balance sheet while also returning substantial cash to shareholders.

As a quick reminder, on April 11, SIGA paid a cash dividend of $0.60 per share, which amounted to a $43 million payment to shareholders.

Looking forward, as Diem mentioned earlier in the call, we are well positioned for substantial revenues in the fourth quarter and into 2025, in light of our outstanding order balance of $146 million as of September 30. As such, we believe 2024 is lining up to be another year of strong product revenue performance. This concludes the financial update.

At this point, I will turn the call back to Diem.

[Diem Nguyen, executive]

Thank you, Dan. With that, we would like to open the call for questions.

[Operator]

[Operator Instructions] Your first question comes from Jyoti Prakash at Edison Group.

[Jyoti Prakash, analyst]

I have around 3 to 4 questions. So let me ask them one after the other. It's great to see that the deliveries under the BARDA order for oral TPOXX have started happening in Q4. My question is related to the deliveries of IV TPOXX, which seem to be more protracted in comparison to oral TPOXX. What are the reasons for this? Are there any particular supply chain-related constraints? When can we see orders being delivered for IV TPOXX? Secondly, when can we expect the latest order from the Department of Defense to be delivered?

[Diem Nguyen, executive]

So Jyoti, thank you so much for your first question. I will start by first giving you a little context between oral TPOXX as well as the IV. Oral TPOXX is the predominant formulation of the U.S. government stockpile and, in connection with its delivery activity, the timing and the cadence of the order activity is very, very different between the 2 formulations, whether it's orals or IV.

The manufacturing process for IV is much more complex than the oral process for TPOXX with the use of different vendors as well as some different raw materials. Given these differences, IV and oral TPOXX are on different schedules, with IV requiring longer manufacturing lead times than oral.

Lastly, product deliveries, whether it's IV or orals, are partially dependent on whether customers would like to take -- when the customers would like to take delivery. As Dan mentioned, the timing of the orals from the last contract tranche has started in 2024 and will continue into 2025.

[Jyoti Prakash, analyst]

Okay. That's helpful. And just on the question on the deliveries under the Department of Defense contract.

[Diem Nguyen, executive]

I think I...

[Daniel Luckshire, executive]

The timing share.

[Diem Nguyen, executive]

Yes. And I said that the deliveries have started already this year and will continue into 2025.

[Jyoti Prakash, analyst]

Okay. And the second question is related to your internationalization efforts. It's great to see you make your commercial foray into Africa. Just want to understand, since your amendment -- agreement of your amendment with Meridian, how -- what kind of traction opportunities or challenges are you seeing in the international markets?

[Diem Nguyen, executive]

So thank you. As a gentle reminder for the broad audience, we amended the Meridian agreement effective in June 1, so that we could bring all the international marketing sales in-house, except for a few administrative and supportive activities provided by Meridian.

This change has given us greater control to meet the needs of our global customers. Since amending the agreement, we have been spending considerable time strengthening and building our relationships with current as well as potential customers around the globe. We're all centered around the expanding of our international business.

With the recent sale of Africa to the request of the Ministry of Health of Morocco, we believe our effort is off to a great start. Bringing the effort in-house has definitely enhanced our depth and dialogue with international customers, and we expect it will help our ongoing efforts to pursue sales opportunities over the immediate and long-term horizon. We have not experienced any challenges at this point in this transition.

[Jyoti Prakash, analyst]

Perfect. And moving on, it's great to see that you've in-licensed a new preclinical program. Can you provide us some more details on the deal economics? And when can we expect this program to enter clinical studies? And how do you plan to develop this as a monotherapy or a combination therapy with TPOXX?

[Diem Nguyen, executive]

Sure. Thank you for asking. We're extremely excited about the recent in-license of the monoclonal antibody portfolio from Vanderbilt. And we're excited about this opportunity to expand our pipeline and strengthen our ability to be in the orthopox space.

These antibodies, we believe, have a potential to treat a broad spectrum of orthopoxviruses, which is inclusive of smallpox and mpox, and we would look to develop them from a therapeutic as well as a prophylactic consideration. We've demonstrated promise in preclinical models and could potentially use as a stand-alone treatment or in the combination with TPOXX.

Given our capabilities in clinical development as well as partnerships in the U.S. government agencies, we believe we're best suited to maximize the potential of these therapies in a cost-effective manner. In fact, the DoD has recently funded the development through a third party with monoclonal antibody manufacturing expertise through Phase I. As we work through the clinical development process, we will keep you posted. It's premature to talk about timing.

[Jyoti Prakash, analyst]

Excellent. And I have one final question. There have been recent media reports on some mpox patients being resistant to TPOXX. Can you provide your perspective on these reports and if that's a concern for SIGA?

[Diem Nguyen, executive]

Thank you for giving us an opportunity to weigh in on some of these reports as it relates to resistance. I always think it's important to think about considerations based on totality of data.

I will first start with by saying that the preclinical evidence collected to date has shown no resistance in animals treated with TPOXX for an extended time frame. Additionally, CDC reports document only a small number of drug resistance developing in patients receiving TPOXX. Overall, it remains low, at less than 1% in the patient population.

This resistance has been primarily observed in a limited number of immunocompromised patients or those with advanced HIV who have received extended courses of treatment beyond the recommended duration. I think the recent report you're referring to is the October CDC Morbidity and Mortality Weekly Report.

This has noted a small sample of patients with mild mpox. Resistance to TPOXX was reported in a few patients. This finding is potentially important and does warrant further investigation to guide future treatment protocols. However, I think it's important to note that the treatment history documentation was not collected to better understand these reports.

And additionally, these reports omit important data related to the total number of specimens tested, patient profiles as well as treatment timing, making it difficult to reach a conclusion about tecovirimat's efficacy in mpox treatment or overall detection of drug resistance.

It's really important to note that the resistance of smallpox or mpox is less likely to occur compared to COVID-19 or influenza. For example, smallpox and mpox are DNA viruses, which mutate less easily than RNA viruses like the viruses that I just mentioned, COVID and influenza. This may attribute it to the low levels of resistance observed to date with tecovirimat.

I would like to remind everyone that there is no demonstrated tecovirimat resistance to smallpox, and we have not identified that to date.

[Operator]

It appears we have no further questions. I will turn the call back over for closing comments.

[Diem Nguyen, executive]

Thank you so much for dialing in to SIGA's call and for your ongoing interest in our company. We look forward to speaking to you again on our fourth quarter call. Have a good rest of the evening.

[Operator]

Ladies and gentlemen, this concludes your conference for today. We thank you for participating, and we ask that you please disconnect your lines.